US EditionRussian Cancer Vaccine Offers Hope, but It Is Still Not a Breakthrough
9 Articles
9 Articles
The Federal Medical and Biological Agency of Russia (FMBA) confirmed that, several studies replicated over three years confirmed that, the Enteromix vaccine is safe even with repeated applications to treat cancer patients. According to international media, the initial phase will focus on patients with colorectal cancer, with the aim of verifying its effectiveness in a specific type of tumor. Oncologist Andrei Kaprin stated that treatment will ha…
The drug, called EnteroMix, showed encouraging results in preclinical tests and is now evaluated in patients to confirm its safety and efficacy.
Russia has just announced that its first domestically developed cancer vaccine is ready for use, with the ability to shrink tumors by up to 80% and improve survival rates for patients.
Russia’s Cancer Vaccine Shows High Efficacy In Preclinical Trials
Russia’s critical cancer vaccine has passed preclinical trials with tests showing that it is safe and highly effective, marking a major breakthrough for cancer treatment. The research for this vaccine took several years, while the final trials lasted three years. The vaccine now awaits approval before it can be used in patients. Veronika Skvortsova of the Federal Medical and Biological Agency (FMBA) announced the news at the Eastern Economic For…
BREAKING NEWS!! Russia Officially Announces Cancer Vaccine Ready For Clinical Use, Rolled Out To Patients For Free
Russia has officially announced the development of a new cancer vaccine, now ready for clinical use and set to be provided to patients free of charge. The announcement was made during the Eastern Economic Forum in Vladivostok, where health officials confirmed that hospitals across the country will soon begin administering the vaccine. The vaccine, named Enteromix, uses advanced mRNA technology, the same scientific approach employed in COVID-19 v…
Coverage Details
Bias Distribution
- 100% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
